Dr. Paul Schumacker PhD provides an overview of the Red Journal's status, including a summary of its scientific scope, the editorial process, current Journal statistics, and future initiatives designed to attract submissions from junior investigators, and to promote the career development of new investigators who publish in the Journal.

1. AN INTRODUCTION TO THE AJRCMB
STATISTICS, INITIATIVES, AND MORE
PAUL SCHUMACKER // EDITOR-IN-CHIEF

2. MEET
THE
EDITORS
EDITOR-IN-CHIEF
Paul Schumacker, PhD
DEPUTY EDITOR
Gregory Downey, MD
DEPUTY EDITOR
Susanne Herold, PhD
ASSOCIATE EDITORS
Carla Kim, PhD
Tomoko Betsuyaku,
PhD
Louise Donnelly,
PhD
Stella
Kourembanas, MD
Rama
Mallampalli, MD
Gokhan Mutlu,
MD
Charles Powell, MD Annie Pardo, PhD Karen Ridge, PhD Victor Thannickal, MD
Norbert
Weissmann, PhD

3. NEW
INITIATIVES
AT THE
AJRCMB
Assure fairness and transparency in the editorial process
Increase Editorials to highlight Original Contribution articles
Encourageinvited author to include a juniorcolleague to co-author
Shorten the time-to-first decision for manuscripts
Assign 2 editors to make decisionson immediate rejections
Publish high-quality Translational Reviews and Perspective articles
Solicit high quality Original Contributions during interactions at meetings
Increase submission rate while sustaining acceptance rate
Institute a formal appeals process for when authors dispute a decision
Commission audio podcasts to draw attention to the Journal
Interview senior investigators as an overview of emerging topics
Promote the Journal as an attractive forum for junior investigators
Improve the A JRCMB Impact Factor without losing sight of our mission

4. TRANSFERS
FROM
AJRCCM
AJRCCM à AJRCMB
2015 78Transferred Acceptance Rate: 28%
95Transferred Acceptance Rate: 30%
19*
Transferred Acceptance Rate: 31%
2016
2017
*As of April 2017

5. ORIGINAL
CONTRIBUTIONS
TOP 15 COUNTRIES
2013 2014
USA 242
China 54
Canada 31
Japan 27
United Kingdom 19
Germany 18
Netherlands 16
Italy 13
Taiwan 12
Australia 11
South Korea 10
France 10
Sweden 8
Spain 8
Belgium 5
USA 203
China 39
Canada 27
Germany 22
Japan 22
United Kingdom 21
Australia 17
South Korea 17
Netherlands 12
France 11
Italy 8
Switzerland 6
Sweden 6
Spain 5
Taiwan 5
USA 151
China 40
Japan 33
Germany 19
Australia 16
United Kingdom 13
Italy 11
France 10
Canada 10
Netherlands 10
Taiwan 6
Belgium 5
Brazil 5
South Korea 5
Sweden 5
2015
Authors from 38 countries contributedAuthors from 35 countries contributedAuthors from 33 countries contributed
US 176
China 32
Canada 20
Japan 20
Australia 18
United Kingdom 18
Netherlands 10
Germany 9
France 8
South Korea 10
Sweden 6
Italy 5
Spain 5
Brazil 3
Belgium 2
2016
Authors from 38 countries contributed

6. ACCEPTANCE
RATE
44%
35%
32%
36%
28%
0%
20%
40%
60%
80%
2013 2014 2015 2016 2017
Jan - Apr
ORIGINAL RESEARCH

7. TURNAROUND
TIME
20
18
16 16
12
0
10
20
30
40
2013 2014 2015 2016 2017
DAYS TO FIRST DECISION

8. TURNAROUND
TIME
DAYS TO FIRST DECISION
Last 6 Months
Turnaround in days for Associate
Editors to make first decisions 13 Days*
Turnaround in days for Associate
Editors to make first decisions
(excluding direct rejects)
22 Days*
All manuscript types are included
*”Mean” average

9. BEST JUNIOR
INVESTIGATOR
AWARD
2016
Identification of Epithelial Phospholipase A2
Receptor 1 as a Potential Target in Asthma
James D. Nolin , H. Luke Ogden , Ying Lai , William A. Altemeier , Charles W.
Frevert , James G. Bollinger , Gajendra S. Naika , Anthony Kicic , Stephen M.
Stick , Gerard Lambeau , William R. Henderson Jr., Michael H. Gelb , and Teal S.
Hallstrand
Am J Respir Cell Mol Biol. 2016 Dec;55(6):825-836.
doi: 10.1165/rcmb.2015 0150OC
James D. Nolin, Ph.D.
University of Washington

10. 2017 ACCEPTED
REVIEW
ARTICLES
Lymphatic Changes in Respiratory Diseases: More Than Just Remodeling of the Lung?
Souheil El-Chemaly
The Role of NOD-like Receptors in Pulmonary Infection.
Kristin Wiese et al.
Metabolism and Skeletal Muscle Homeostasis in Lung Disease.
Jacob Sznajder et al.
MicroRnas Profiling in Asthma: Potential Biomarkers and Therapeutic Targets.
Enrico Heff et al.
TRANSLATIONAL REVIEWS
When is an Alveolar Type 2 Cell an Alveolar Type 2 Cell? A Conundrum for Lung Stem Cell Biology and
Regenerative Medicine.
Michael Beers et al.
PERSPECTIVES
Unbiased Quantitation of ATII to ATI Cell Transdifferentiation During Repair After Lung Injury in Mice
Rachel Zemans et al.
MAJOR TECHNICAL ADVANCES
ATS DOCUMENT
An Official American Thoracic Society Workshop Report: Use of AnimalModels for the Preclinical Assessment
of Potential Therapies for Pulmon.

11. ACCEPTED
RESEARCH
ARTICLES AND
REVIEWS
Year Research Articles
(OC’s)
Features
(Perspectives, Translational Reviews and
Major Technical Advances)
Total
2017
(Jan - Apr)
46 6 52
2016 116 26 142
2015 127 18 145
2014 168 27 195
2013 232 15 247

12. ACCEPTED
EDITORIALS AND
LETTERS TO THE
EDITOR
Year Editorials Letters
2017
(Jan - Apr)
28 3
2016 12 8
2015 1 7
2014 3 2
2013 2 4

13. PUBLAG
Time from Official Acceptance
to Final Online Version
3.6
4.6
6.6
5.2
3.6
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
2013 2014 2015 2016 2017
Note: The lag time is the “mean” average for the year
Months

14. IMPACT
FACTOR
4.16
4.17
4.01
4.17
3.99
4.59
4.61
4.48
4.32
4.43 5.12
4.15
4.11
3.99
4.08
0.00
2.00
4.00
6.00
8.00
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
?

15. PUBLICATION
LAG
OFFICIAL ACCEPTANCE TO
ONLINE PUBLICATION
Accepted papers are published online
within 48 hours on the ATS journal
website. They will have Digital Object
Identifiers (DOIs), so they are citable
and indexed by PubMed, CrossRef,
Google, etc.

16. EDITORIAL
PROCESS
Editorial staff checks newly submitted
manuscripts
Allocated to EiC’s Queue
EiC
Manuscript sent for review (two or
more reviewers assigned) Editorial Staff prepares for
early online publication
and final online version
Plagiarism
check
Image
forensics
check
Reviewing Editor
Confers with AE
Accept
Revised paper
resubmitted
Associate Editor
Evaluates manuscript
Reject without
external review
Reject after
review
Major
Revision
Minor
Revision
START
END